Current Edition

Upcoming Events

Advertisement

news

Medical AI startup Synyi raises $15.7 M

Synyi will use the fund to develop medical natural language processing, medical data governance and machine learning. Venture capital firm GGV Capital has led a RMB...
Continue Reading →
news

Korea to invest $33.4M in medical AI system

The ministry plans to carry out this medical artificial intelligence project over the course of three years. The South Korean government plans to invest 35.7 billi...
Continue Reading →
news

Cellmid inks deal with China’s Fukangren Bio-pharm

The deal aims to distribute Cellmid's évolis and anti-aging hair care products in the Peoples Republic of China Australia based Cellmid has recently announced that ...
Continue Reading →
news

Haselmeier and Common Sensing Enter Connected Injectable Medicine Collaboration

Haselmeier, a Swiss-based developer and manufacturer of innovative self-injection devices, and Common Sensing, a Cambridge-based smart injector monitoring and support...
Continue Reading →
news

Q1 earnings preview: Novo, Celgene still to come

It hasn't been the prettiest first quarter for drugmakers. Sanofi's revenue fell, as did confidence in one of the company's key growth drivers. Allergan discussed a s...
Continue Reading →
news

For Expensive New Drugs, Biopharma Should Make Money-Back Guarantees Mandatory

In a recent paper on “Value-Based Pricing for Drugs”, authors Anna Kaltenboeck and Peter B. Bach of the Memorial Sloan Kettering Cancer Center discuss the high cost o...
Continue Reading →
news

ExpreS2ion’s U.S. partner Integrated BioTherapeutics launches first ExpreS2-based research product

ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that its U.S.-based partner and licensee Integrated BioTherapeutics (“IBT”) has initiated sales and marketin...
Continue Reading →
news

Saunders: All options remain on the table for Allergan

Brief: Allergan CEO Brent Saunders said Monday the Irish pharma is considering a wide range of business options, including further divestitures or a split of the ...
Continue Reading →
news

United Therapeutics nabs competing PAH drug with $216M SteadyMed buy

Brief: United Therapeutics announced Monday morning that it will acquire competitor SteadyMed for $4.46 per share in cash upfront and another $2.63 per share in c...
Continue Reading →
news

Sparks sells regulatory fast pass to Jazz for $110M

Brief: Spark Therapeutics has sold a priority review voucher (PRV) to Jazz Pharmaceuticals for $110 million, according to a Monday disclosure. While details wer...
Continue Reading →